BC Children’s & Women’s Hospital
Details
Program / division
Pediatric Hemophilia Clinic
Address
4500 Oak Street
Room T8-503
Vancouver BC V6H 3N1
Canada
Contact
604-875-2345, ext. 5335
AHCDC members
-
Dr. Mark Belletrutti
Pediatric Hematologist
Clinical trials
| Trial Name | Condition | Phase | Status | Details | ||
|---|---|---|---|---|---|---|
| NN7415-4616 (EXPLORER 10) NCT05135559 | Males below 12 years of age with HAwI, HBwI, or HA or HB without inhibitors | 3 | Closed to enrollment Last updated Mar 2026 | |||
|
Objective: Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors Contact: study@htc.ca |
||||||
| WP44714 (NXT007) NCT05987449 | Multiple See details | 1/2 | Recruiting Last updated Mar 2026 | |||
|
Objective: Contact: study@htc.ca Part 1: Adolescent and adult male participants aged ≥12 and <60 years with severe or moderate HA on previous prophylactic or on-demand treatment with FVIII concentrate or HA with FVIII inhibitors on previous prophylactic or on-demand bypass agent (rFVIIa or aPCC) Primary objective: To evaluate the safety of multiple doses of NXT007. Secondary Objectives: (1) To characterize the pharmacokinetics of NXT007 following multiple doses of NXT007, (2) To evaluate the immunogenicity of multiple doses of NXT007, (3) To evaluate the recurrence of or de novo FVIII inhibitor occurrence, and change to FVIII inhibitor titer over time, (4) To explore the efficacy of multiple doses of NXT007. |
||||||